---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-013468"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:37:42.100041+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma signs non-binding MoU with HelixNano for thermostable mRNA vaccine development

## Summary
- Non-binding MoU to combine Medicus' MNA delivery platform with HelixNano's mRNA platform for thermostable infectious disease vaccines.
- Parties aim to form a joint venture for co-development and commercialization of thermostable mRNA-based vaccines.
- Plan a Phase 1 bridging study comparing IM injection vs. intradermal MNA delivery of HelixNano's vaccine candidate HN-0001.
- Preliminary activities include a Sponsored Research Agreement with University of Pittsburgh (Dr. Lou Falo), supply of HN-0001, and loading into Medicus' MNAs.
- MoU is non-binding; no obligation to proceed with joint venture until definitive agreements are executed.

## SEC filing metadata
- accession: 0001062993-25-013468
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325013468/0001062993-25-013468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325013468/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-013468
- JSON: https://secwatch.observer/filing/0001062993-25-013468.json
- Plain text: https://secwatch.observer/filing/0001062993-25-013468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.